z-logo
open-access-imgOpen Access
Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease
Author(s) -
Madany Emaan,
Lee June,
Halprin Chelsea,
Seo Jina,
Baca Nicole,
Majlessipour Fataneh,
Hendrickson Jeanne E.,
Pepkowitz Samuel H.,
Hayes Chelsea,
Klapper Ellen,
Gibb David R.
Publication year - 2021
Publication title -
ejhaem
Language(s) - English
Resource type - Journals
ISSN - 2688-6146
DOI - 10.1002/jha2.270
Subject(s) - peripheral blood mononuclear cell , immunology , proinflammatory cytokine , interferon , medicine , immune system , sickle cell anemia , disease , gene , inflammation , biology , biochemistry , in vitro
Patients with sickle cell disease (SCD) have a high prevalence of RBC alloimmunization. However, underlying mechanisms are poorly understood. Given that proinflammatory type 1 interferons (IFNα/β) and interferon stimulated genes (ISGs) promote alloimmunization in mice, we hypothesized that IFNα/β may contribute to the increased frequency of alloimmunization in patients with SCD. To investigate this, expression of ISGs in blood leukocytes and peripheral blood mononuclear cells (PBMCs) of previously transfused SCD patients with or without alloimmunization and race‐matched healthy controls were quantified, and IFNα/β gene scores were calculated. IFNα/β gene scores of SCD leukocytes and plasma cytokines were elevated, compared to controls (gene score, p  < 0.01). Upon stimulation with IFNβ, isolated PBMCs from patients with SCD had elevated ISGs and IFNα/β gene scores ( p  < 0.05), compared to stimulated PBMCs from controls. However, IFNβ‐stimulated and unstimulated ISG expression did not significantly differ between alloimmunized and non‐alloimmunized patients. These findings indicate that patients with SCD express an IFNα/β gene signature, and larger studies are needed to fully determine its role in alloimmunization. Further, illustration of altered IFNα/β responses in SCD has potential implications for IFNα/β‐mediated viral immunity, responses to IFNα/β‐based therapies, and other sequelae of SCD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here